Onesource Specialty Pharma Limited Stock Price Today (NSE: ONESOURCE)
Fundamental Score
Onesource Specialty Pharma Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Onesource Specialty Pharma Limited share price today is ₹1596.60, down 0.19% on NSE/BSE as of 16 September 2026. Onesource Specialty Pharma Limited (ONESOURCE) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹18.30K (Cr). The 52-week high for ONESOURCE share price is ₹1925.00 and the 52-week low is ₹1057.00. The company has a Return on Equity (ROE) of -1.26% and a debt-to-equity ratio of 0.22.
Onesource Specialty Pharma Limited Share Price Chart — NSE/BSE Historical Performance
Onesource Specialty Pharma Limited share price chart: 0.26% return over the past month. 52-week high ₹1925.00, 52-week low ₹1057.00.
Onesource Specialty Pharma Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1595.00 | ₹1613.60 | ₹1563.20 | ₹1596.60 | 1.43L (Cr) | |
| ₹1614.90 | ₹1657.50 | ₹1589.00 | ₹1599.60 | 7.25L (Cr) | |
| ₹1548.10 | ₹1624.70 | ₹1530.00 | ₹1592.20 | 9.19L (Cr) | |
| ₹1526.00 | ₹1567.80 | ₹1526.00 | ₹1541.90 | 2.47L (Cr) | |
| ₹1590.00 | ₹1617.00 | ₹1510.10 | ₹1530.10 | 24.11L (Cr) | |
| ₹1560.00 | ₹1645.70 | ₹1557.50 | ₹1579.50 | 7.07L (Cr) | |
| ₹1552.90 | ₹1573.00 | ₹1530.00 | ₹1552.30 | 1.40L (Cr) | |
| ₹1585.00 | ₹1596.30 | ₹1526.00 | ₹1537.80 | 1.13L (Cr) | |
| ₹1559.00 | ₹1596.60 | ₹1546.00 | ₹1575.70 | 1.19L (Cr) | |
| ₹1530.00 | ₹1564.00 | ₹1509.00 | ₹1544.40 | 1.36L (Cr) |
Onesource Specialty Pharma Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1529.90 | ₹1657.50 | ₹1504.10 | ₹1596.60 | +4.36% | |
| ₹1624.00 | ₹1647.00 | ₹1478.00 | ₹1519.10 | -6.46% | |
| ₹1665.00 | ₹1755.20 | ₹1506.10 | ₹1619.70 | -2.72% | |
| ₹1793.00 | ₹1895.00 | ₹1530.30 | ₹1647.80 | -8.10% | |
| ₹1774.00 | ₹1917.80 | ₹1704.70 | ₹1824.60 | +2.85% | |
| ₹1480.70 | ₹1870.00 | ₹1316.40 | ₹1738.10 | +17.38% | |
| ₹1289.60 | ₹1542.80 | ₹1231.00 | ₹1473.30 | +14.24% | |
| ₹1200.00 | ₹1395.80 | ₹1102.00 | ₹1346.80 | +12.23% | |
| ₹1809.00 | ₹1809.00 | ₹1057.00 | ₹1194.50 | -33.97% | |
| ₹1536.00 | ₹1824.00 | ₹1515.20 | ₹1810.60 | +17.88% | |
| ₹1854.10 | ₹1925.00 | ₹1494.70 | ₹1532.20 | -17.36% | |
| ₹1823.00 | ₹1896.70 | ₹1775.00 | ₹1854.10 | +1.71% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Onesource Specialty Pharma Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Onesource Specialty Pharma Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ONESOURCE across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Strong Revenue Growth (37.20%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (131.48% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Conservative Debt Levels (D/E: 0.22)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Institutional Confidence (FII+DII: 38.11%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
9 factors identified
Below-Average Return on Equity (-1.26%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (0.46%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-100.00%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Interest Coverage (0.25x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Liquidity Concerns (Current Ratio: 0.98)
Observation: Current assets may not adequately cover short-term liabilities.
Analysis: Current ratio <1.0 raises working capital concerns.
Negative Free Cash Flow (₹-2205.48 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (29.77%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
High Share Pledging Risk (38.38%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Onesource Specialty Pharma Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Onesource Specialty Pharma Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Onesource Specialty Pharma LimitedOnesource Speci...Selected✓ ONESOURCE • 544292 | 0/100 | ₹1596.60₹1597 | ₹18303.42₹18303.42 | — — | -1.26%Poor -1.26% Poor | 0.46%Poor 0.46% Poor | 0.22Excellent 0.2 Excellent | 8.00%Good 8.00% Good | 131.48%Excellent 131.48% Excellent | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9467.50₹9468 | ₹250888.75₹250888.75 | 85.90Average 85.9 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4939.50₹4940 | ₹167182.32₹167182.32 | 78.91Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1371.90₹1372 | ₹110828.94₹110828.94 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.10₹1941 | ₹104867.93₹104867.93 | 95.81Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1683.00₹1683 | ₹96839.82₹96839.82 | 26.30Average 26.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.70₹2101 | ₹96054.51₹96054.51 | 17.36Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1144.50₹1145 | ₹95565.75₹95565.75 | 29.58Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2293.70₹2294 | ₹94729.81₹94729.81 | 46.35Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price250888.75 Cr
- Torrent Pharmaceuticals Limited share price167182.32 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110828.94 Cr
Onesource Specialty Pharma Limited Quarterly Performance
Latest quarterly metrics for ONESOURCE — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
37.20%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-100.00%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
131.48%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
8.00%
Compounded annual net profit growth over 5 years
Onesource Specialty Pharma Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ONESOURCE — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Onesource Specialty Pharma Limited Financial Statements
Annual income statement, balance sheet and cash flow for Onesource Specialty Pharma Limited (ONESOURCE) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Onesource Specialty Pharma Limited
About ONESOURCE (Onesource Specialty Pharma Limited)
OneSource Specialty Pharma Inc. is a dynamic pharmaceutical company dedicated to innovating and improving patient lives through specialized drug development and commercialization. ...Focused on niche therapeutic areas, OneSource concentrates its efforts on creating targeted solutions for complex medical conditions where unmet needs persist. Their approach emphasizes rigorous scientific research, cutting-edge formulation technologies, and strategic partnerships to bring high-quality, effective medications to market. The company operates with a commitment to ethical practices and prioritizes patient safety and well-being in every aspect of its operations. OneSource distinguishes itself within the pharmaceutical landscape by integrating research and development with advanced manufacturing capabilities. This synergy allows for streamlined product development cycles, ensuring efficient progression from laboratory to patient. The company's state-of-the-art facilities are equipped to handle a diverse range of dosage forms and delivery systems, including both oral and injectable medications. Furthermore, OneSource actively seeks collaborations with academic institutions and other pharmaceutical companies to leverage expertise and accelerate the discovery and development of novel therapies. Driven by a team of experienced scientists, clinicians, and business professionals, OneSource is committed to expanding its product portfolio and geographic reach. The company's strategic vision involves identifying and capitalizing on emerging market opportunities, while maintaining a steadfast dedication to scientific rigor and patient-centric values. As OneSource continues to grow, it remains dedicated to making a meaningful impact on global healthcare by providing innovative, specialized pharmaceuticals that improve patient outcomes and enhance the quality of life.
Company Details
Key Leadership
ONESOURCE Share Price: Frequently Asked Questions
What is the current share price of Onesource Specialty Pharma Limited?
Onesource Specialty Pharma Limited (ONESOURCE) trades at ₹1596.60 on NSE and BSE. Market cap ₹18.30K (Cr). Educational data only.
What is the P/E ratio of Onesource Specialty Pharma Limited?
Onesource Specialty Pharma Limited has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Onesource Specialty Pharma Limited?
Onesource Specialty Pharma Limited has a Bull Run score of 0/100 based on 25+ financial parameters.
Does Onesource Specialty Pharma Limited pay dividends?
Onesource Specialty Pharma Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Onesource Specialty Pharma Limited?
Onesource Specialty Pharma Limited has ROE of -1.26%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Onesource Specialty Pharma Limited?
Onesource Specialty Pharma Limited has debt-to-equity of 0.22.
Is Onesource Specialty Pharma Limited a good investment?
Bull Run gives Onesource Specialty Pharma Limited a score of 0/100. This is not investment advice — consult a SEBI-registered advisor.